Meeting
2020 ASCO Virtual Scientific Program
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).
Authors
Volker Moebus
Internal Medicine II, Dept. of Hematology & Oncology University of Frankfurt, Frankfurt, Germany
Volker Moebus , Hans-Joachim Lueck , Ekkehart Ladda , Peter Klare , Marcus Schmidt , Andreas Schneeweiss , Michael Untch , Frederik Marmé , Jens Bodo Huober , Elmar Stickeler , Mattea Reinisch , Theresa Link , Bruno Valentin Sinn , Jenny Furlanetto , Toralf Reimer , Christine Solbach , Sabine Schmatloch , Julia Rey , Nicole Burchardi , Sibylle Loibl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT01690702
Citation
J Clin Oncol 38: 2020 (suppl; abstr 516)
DOI
10.1200/JCO.2020.38.15_suppl.516
Abstract #
516
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2).
First Author: Volker Moebus
Poster
2019 Supportive Care in Oncology Symposium
Eflapegrastim, a novel, long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.
First Author: Lee S. Schwartzberg
Poster
2018 ASCO Annual Meeting
Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.
First Author: Volker Moebus
Poster
2017 ASCO Annual Meeting
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).
First Author: Jenny Furlanetto